Bausch + Lomb, an eye health company, has acquired an exclusive global license to a new platform technology from Eye Therapies, LLC, a biopharmaceutical company, that may lead to faster and longer lasting treatment for ocular redness.
According to Baush + Lomb, the technology employs a different mechanism of action to relieve ocular redness than currently available redness relief products, using a low dose of brimonidine. Licensed from Eye Therapies, the technology was developed in collaboration with Ora Inc., a private research organization.
In a Phase II study, the new technology appeared effective in reducing ocular redness based on both clinician assessment and patient reporting. The rebound vasoconstriction associated with currently available treatments was not observed in this study. Additionally, onset of action was shown to be rapid (within five minutes), with a duration of effect lasting at least four hours. The formulation was found to be safe and well tolerated as dosed in the study, with no serious adverse events reported, the company said.
"Ocular redness is associated with reduced quality of life and negative social connotations, and may impact compliance with certain medications," explained Cal Roberts, chief medical officer, Bausch + Lomb. "The decision to license this promising new technology underscores our continued commitment to delivering solutions for physicians and their patients."
"We are proud to be working with Bausch + Lomb to develop this promising new technology," said Lee Nordan, CEO of Eye Therapies, LLC. "The company's commitment, expertise and resources, combined with its global reach, will help ensure that, if approved, this technology will reach its full potential."